• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
B-Cell Lymphomas - Pipeline Review, H1 2012 Product Image

B-Cell Lymphomas - Pipeline Review, H1 2012

  • ID: 2021847
  • January 2012
  • 326 pages
  • Global Markets Direct

B-Cell Lymphomas – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'B-Cell Lymphomas - Pipeline Review, H1 2012', provides an overview of the B-Cell Lymphomas therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Lymphomas. 'B-Cell Lymphomas - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for B-Cell Lymphomas.
- A review of the B-Cell Lymphomas products under development by companies and universities/research institutes READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
B-Cell Lymphomas Overview
Therapeutics Development
An Overview of Pipeline Products for B-Cell Lymphomas
B-Cell Lymphomas Therapeutics under Development by Companies
B-Cell Lymphomas Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
B-Cell Lymphomas Therapeutics – Products under Development by Companies
B-Cell Lymphomas Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in B-Cell Lymphomas Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Abbott Laboratories
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Seattle Genetics, Inc.
Genentech, Inc.
Antigenics, Inc.
MMR Information Systems, Inc.
MedImmune LLC
Gilead Sciences, Inc.
Merck & Co., Inc.
Lentigen Corporation
Micromet, Inc.
Takeda Pharmaceutical Company Limited
ZIOPHARM Oncology, Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Astellas Pharma Inc.
BioMarin Pharmaceutical Inc.
Cephalon, Inc.
Glenmark Pharmaceuticals Ltd.
ImmunoGen, Inc.
Pfizer Inc.
Sunesis Pharmaceuticals, Inc.
SuperGen, Inc.
Teva Pharmaceutical Industries Limited
Cell Therapeutics, Inc.
Genmab A/S
Celgene Corporation
Onyx Pharmaceuticals, Inc.
Bayer AG
Incyte Corporation
Celldex Therapeutics, Inc.
AEterna Zentaris Inc.
IMMUNOMEDICS, INC
InNexus Biotechnology Inc.
MethylGene Inc
Curis, Inc.
Accentia Biopharmaceuticals, Inc.
Allos Therapeutics, Inc
Telik, Inc.
Pharmacyclics, Inc.
MorphoSys AG
Green Cross Corporation
Innate Pharma SA
Piramal Life Sciences Limited
SymBio Pharmaceuticals Limited
Chipscreen Biosciences Ltd
Memgen, LLC.
PanGenetics B.V.
Biolex Therapeutics, Inc.
Ascenta Therapeutics, Inc.
Provenance Biopharmaceuticals Corp.
Celentyx Ltd.
Fresenius Biotech GmbH
Semafore Pharmaceuticals, Inc.
S-BIO Pte Ltd
Onconova Therapeutics, Inc
Immune System Therapeutics Ltd.
Intellikine, Inc.
Xencor, Inc.
VentiRx Pharmaceuticals, Inc.
CureTech Ltd.
Cylene Pharmaceuticals, Inc.
Dynamix Pharmaceuticals Ltd.
Zenyaku Kogyo Co., Ltd.
Probiomed S.A. de C.V.
PharmaTech International, Inc.
B-Cell Lymphomas – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
RG7159 - Drug Profile
Enzastaurin - Drug Profile
MAbThera - Drug Profile
BiovaxID - Drug Profile
Velcade - Drug Profile
Epratuzumab - Drug Profile
Rituximab - Drug Profile
Rituximab + Fludarabine + Cyclophosphamide - Drug Profile
Bendamustine + Rituximab - Drug Profile
Cyclophosphamide + Epirubicin + Vincristine + Prednisone - Drug Profile
Rituximab + Chlorambucil - Drug Profile
Rituximab - Drug Profile
Mitoxantrone + Chlorambucil + Dexamethasone - Drug Profile
Mitoxantrone + Dexamethasone + Fludarabine - Drug Profile
Fludarabine Phosphate - Drug Profile
Chlorambucil For Follicular lymphoma - Drug Profile
Velcade + Rituximab - Drug Profile
Treanda + Rituxan - Drug Profile
Revlimid - Drug Profile
Arzerra + Bendamustine - Drug Profile
Ofatumumab + DHAP - Drug Profile
Pixantrone + Rituximab - Drug Profile
Avastin + R-CHOP - Drug Profile
RG7159 + CHOP - Drug Profile
Filgrastim + Rituximab + Carboplatin + Etoposide + Ifosfamide - Drug Profile
Filgrastim + Rituximab + Carboplatin + Etoposide + Ifosfamide - Drug Profile
Fludarabine + Total Body Irradiation + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile
EPOCH + Rituximab - Drug Profile
Rituximab - Drug Profile
Asparaginase + Cyclophosphamide + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Mercaptopurine + Methotrexate + Methylprednisolone + Mitoxantrone Hydrochloride + Prednisone + Vincristine Sulfate + Radiation Therapy - Drug Profile
Rituximab + Cyclophosphamide + Vincristine + Prednisone + Doxorubicin - Drug Profile
Rituximab + Cyclophosphamide + Hydroxydaunorubicin Hydrochloride + Oncovin + Prednisone - Drug Profile
Rituximab + Cyclophosphamide + Hydroxydaunorubicin Hydrochloride + Oncovin + Prednisone + Darbepoetin Alpha - Drug Profile
VELCADE-R-CAP - Drug Profile
Rituximab + Cyclophosphamide + Fludarabine - Drug Profile
Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Cisplatin + Dexamethasone + Cytarabine + Melphalan + Radiation Therapy + Stem Cell Transplantation - Drug Profile
R-CHOP + Radiation Therapy - Drug Profile
Bexxar + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile
Rituximab - Drug Profile
Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine - Drug Profile
Cyclophosphamide + Doxorubicin + Prednisone + Vincristine + Iodine-131 Tositumomab - Drug Profile
Fludarabine - Drug Profile
FavId + Sargramostim + Rituximab - Drug Profile
Rituximab + Doxorubicin + Vincristine + Prednisone - Drug Profile
Rituximab + Fludarabine + Cyclophosphamide - Drug Profile
Carmustine + Cyclophosphamide + Cytarabine + Etoposide + Melphalan + Autologous Stem Cell Transplantation + Rituximab - Drug Profile
R-CHOP14 + Neulasta - Drug Profile
Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone - Drug Profile
Rituxan + FavId + GM-CSF - Drug Profile
DHAP + Rituximab - Drug Profile
ICE + RITUXIMAB - Drug Profile
Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Rituximab + G-CSF - Drug Profile
Cyclophosphamide + Vincristine + Prednisone + Epirubicin + Rituximab + G-CSF - Drug Profile
Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Rituximab + G-CSF - Drug Profile
R-FM - Drug Profile
R-CVP - Drug Profile
Cyclophosphamide + Prednisone + Epirubicin + Vinblastine + Rituximab + G-CSF - Drug Profile
R-CHOP14 + Darbepoetin Alfa - Drug Profile
Rituximab-HDS - Drug Profile
Bleomycin Sulfate + Rituximab + CHOP Regimen + EPOCH Regimen + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Methotrexate + Mitoxantrone Hydrochloride + Prednisolone + Prednisone + Vincristine Sulfate - Drug Profile
Filgrastim + Recombinant Interferon Alfa + Carmustine + Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Melphalan + Radiation Therapy + Peripheral Blood Stem Cell Transplantation - Drug Profile
Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine + Filgrastim + Carboplatin + Etoposide + Ifosfamide - Drug Profile
Lenalidomide - Drug Profile
R-CHOP - Drug Profile
Revlimid + Rituxan - Drug Profile
Biosimilar Rituximab - Drug Profile
PBO-326 - Drug Profile
Bortezomib + Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisolone - Drug Profile
B-Cell Lymphomas Therapeutics – Drug Profile Updates
B-Cell Lymphomas Therapeutics – Discontinued Products
B-Cell Lymphomas Therapeutics - Dormant Products
B-Cell Lymphomas – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for B-Cell Lymphomas, H1 2012
Products under Development for B-Cell Lymphomas – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Development by Companies, H1 2012 (Contd..4)
Number of Products under Development by Companies, H1 2012 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Development by Companies, H1 2012 (Contd..5)
Products under Development by Companies, H1 2012 (Contd..6)
Products under Development by Companies, H1 2012 (Contd..7)
Products under Development by Companies, H1 2012 (Contd..8)
Products under Development by Companies, H1 2012 (Contd..9)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..19)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..20)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..21)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..22)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..23)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..24)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..25)
Bristol-Myers Squibb Company, H1 2012
Genzyme Corporation, H1 2012
Johnson & Johnson, H1 2012
F. Hoffmann-La Roche Ltd., H1 2012
Kyowa Hakko Kirin Co., Ltd., H1 2012
Abbott Laboratories, H1 2012
Amgen Inc., H1 2012
Sanofi-Aventis, H1 2012
AstraZeneca PLC, H1 2012
Eli Lilly and Company, H1 2012
GlaxoSmithKline plc, H1 2012
Seattle Genetics, Inc., H1 2012
Genentech, Inc., H1 2012
Antigenics, Inc., H1 2012
MMR Information Systems, Inc., H1 2012
MedImmune LLC, H1 2012
Gilead Sciences, Inc., H1 2012
Merck & Co., Inc., H1 2012
Lentigen Corporation, H1 2012
Micromet, Inc., H1 2012
Takeda Pharmaceutical Company Limited, H1 2012
ZIOPHARM Oncology, Inc., H1 2012
Millennium Pharmaceuticals, Inc., H1 2012
Novartis AG, H1 2012
Astellas Pharma Inc., H1 2012
BioMarin Pharmaceutical Inc., H1 2012
Cephalon, Inc., H1 2012
Glenmark Pharmaceuticals Ltd., H1 2012
ImmunoGen, Inc., H1 2012
Pfizer Inc., H1 2012
Sunesis Pharmaceuticals, Inc., H1 2012
SuperGen, Inc., H1 2012
Teva Pharmaceutical Industries Limited, H1 2012
Cell Therapeutics, Inc., H1 2012
Genmab A/S, H1 2012
Celgene Corporation, H1 2012
Onyx Pharmaceuticals, Inc., H1 2012
Bayer AG, H1 2012
Incyte Corporation, H1 2012
Celldex Therapeutics, Inc., H1 2012
AEterna Zentaris Inc., H1 2012
IMMUNOMEDICS, INC, H1 2012
InNexus Biotechnology Inc., H1 2012
MethylGene Inc, H1 2012
Curis, Inc., H1 2012
Accentia Biopharmaceuticals, Inc., H1 2012
Allos Therapeutics, Inc, H1 2012
Telik, Inc., H1 2012
Pharmacyclics, Inc., H1 2012
MorphoSys AG, H1 2012
Green Cross Corporation, H1 2012
Innate Pharma SA, H1 2012
Piramal Life Sciences Limited, H1 2012
SymBio Pharmaceuticals Limited, H1 2012
Chipscreen Biosciences Ltd, H1 2012
Memgen, LLC., H1 2012
PanGenetics B.V., H1 2012
Biolex Therapeutics, Inc., H1 2012
Ascenta Therapeutics, Inc., H1 2012
Provenance Biopharmaceuticals Corp., H1 2012
Celentyx Ltd., H1 2012
Fresenius Biotech GmbH, H1 2012
Semafore Pharmaceuticals, Inc., H1 2012
S-BIO Pte Ltd, H1 2012
Onconova Therapeutics, Inc, H1 2012
Immune System Therapeutics Ltd., H1 2012
Intellikine, Inc., H1 2012
Xencor, Inc., H1 2012
VentiRx Pharmaceuticals, Inc., H1 2012
CureTech Ltd., H1 2012
Cylene Pharmaceuticals, Inc., H1 2012
Dynamix Pharmaceuticals Ltd., H1 2012
Zenyaku Kogyo Co., Ltd., H1 2012
Probiomed S.A. de C.V., H1 2012
PharmaTech International, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
B-Cell Lymphomas Therapeutics – Drug Profile Updates
B-Cell Lymphomas Therapeutics – Discontinued Products
B-Cell Lymphomas Therapeutics – Discontinued Products (Contd..1)
B-Cell Lymphomas Therapeutics – Discontinued Products (Contd..2)
B-Cell Lymphomas Therapeutics – Discontinued Products (Contd..3)
B-Cell Lymphomas Therapeutics – Dormant Products
B-Cell Lymphomas Therapeutics – Dormant Products (Contd..1)
B-Cell Lymphomas Therapeutics – Dormant Products (Contd..2)
B-Cell Lymphomas Therapeutics – Dormant Products (Contd..3)
B-Cell Lymphomas Therapeutics – Dormant Products (Contd..4)
B-Cell Lymphomas Therapeutics – Dormant Products (Contd..5)
B-Cell Lymphomas Therapeutics – Dormant Products (Contd..6)
B-Cell Lymphomas Therapeutics – Dormant Products (Contd..7)
B-Cell Lymphomas Therapeutics – Dormant Products (Contd..8)
B-Cell Lymphomas Therapeutics – Dormant Products (Contd..9)
B-Cell Lymphomas Therapeutics – Dormant Products (Contd..10)

List of Figures
Number of Products under Development for B-Cell Lymphomas, H1 2012
Products under Development for B-Cell Lymphomas – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos